Senate Seeks Details Of Antidepressant Suicide Data Evaluation By Columbia University
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Charles Grassley is requesting information on the "rationale" for a non-FDA review of the data. The request is part of an ongoing investigation of the agency's handling of suicide-related events in pediatric antidepressant data.
You may also be interested in...
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.
FDA Antidepressant Data Was Fully Disclosed, Agency Tells Congress
Although there was internal disagreement on the implications of pediatric antidepressant data, all information was reviewed publicly, the agency maintains in a letter to the House Energy & Commerce/Oversight Subcommittee.